Eczema Awareness Monthly – An American Academy of Dermatology Official Licensee
0
  • Eczema
  • Articles
  • Expert Panel
  • Guidelines
  • Studies
  • Systematic Reviews
  • Patient Resources
Eczema Awareness Monthly - An American Academy of Dermatology Official Licensee
0
Eczema Awareness Monthly - An American Academy of Dermatology Official Licensee
  • Eczema
  • Articles
  • Expert Panel
  • Guidelines
  • Studies
  • Systematic Reviews
  • Patient Resources
Advertisement
ArticlesEczema

DW Weekly: FDA approves crisaborole for AD patients as young as three months

Awareness Monthly
Posted by Awareness Monthly

Officials with the FDA have approved crisaborole (Eucrisa) ointment, 2%, for use in children as young as 3 months of age with mild-to-moderate atopic dermatitis.

Learn more at the American Academy of Dermatology.

Share on
Share on Facebook Share on Twitter Share on Pinterest Share on Email
Awareness Monthly
Previous Article Prevalence of asthma in patients with atopic dermatitis
Next Article DermWorld: Does the burden of atopic dermatitis vary by age, race, ethnicity?
Advertisement

 

Advertisement

 

You Might Also Enjoy

ArticlesEczema

First Topical JAK Inhibitor for Atopic Dermatitis Receives FDA Approval

ArticlesEczema

Pediatric Atopic Dermatitis: Topical Calcineurin Inhibitors

ArticlesEczema

Atopic Dermatitis and COVID-19 Infection Risk

ArticlesEczema

Biologic for Atopic Dermatitis FDA Approved

Load More
Eczema Awareness Monthly - An American Academy of Dermatology Official Licensee

© 2020-2023 Powered by eHealthcare Solutions | Privacy Policy

×